MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Submits Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System to the Slovenian Intellectual Property Office. MGC Pharma expects the patent to be issued within the next 12 months.
Co-founder and Managing Director Roby Zomer comments: "The acceptance of this patent could be transformational for patients who need treatment and therapeutic relief from neurological diseases. The new IP will not only improve MGC Pharma's current formulations, including our phytocannabinoid-based drugs CannEpil and CogniCann, but potentially provide more affordable medicines for patients as a result of the more efficient use of resources in formulations.
"The submission to SIPO provides MGC Pharma with the right to file further applications in multiple jurisdictions and treat people and patients suffering from these conditions on a global scale."
Current stock price: 2.05 pence
Year-to-date change: up 39% from February IPO price of 1.48p
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.